Recruiting
Phase 1
Phase 2

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Sponsor:

Benitec Biopharma, Inc.

Code:

NCT06185673

Conditions

Oculopharyngeal Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 0 - 65

Healthy Volunteers: Not accepted

Interventions

BB-301: Dose escalation phase 1b cohort 1

BB-301: Dose escalation phase 1b cohort 2

BB-301: Dose escalation phase 1b cohort 3

BB-301: Dose expansion phase 2a

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information